Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Lyn Baranowski
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 55
- Beta
- -1.13
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 24.20
Financials
AVLN has only 6 quarterly periods on file — the charts below show the full history available.
Net Income
$-29.66MEBITDA
$-33.09MFree Cash Flow
$-26.34MEPS (diluted)
$-0.67Shares Outstanding (diluted)
44.39M+6.2%Operating Expenses
$33.09MCash & Debt
$327.46MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-85.20M | $-2.04 |
| 2024 | $0.00 | $-49.74M | $-1.19 |
Valuation
AVLNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (6)
- Newsseekingalpha.com·3d ago·Neutral
Avalyn Pharma: The Tolerability Budget Is The Real Battleground In Pulmonary Fibrosis Avalyn Pharma offers lung-directed delivery of proven antifibrotics, potentially preserving tolerability as IPF and PPF regimens incorporate additional systemic agents. AP01 targets PPF label expansion, while AP02 and combination candidate AP03 offer additional opportunities; delivery and tolerability remain key uncertainties. MIST, AURA, and AP03 data are expected in the second half of 2027; Tyvaso's April dec
View source ↗ - Newsglobenewswire.com·62d ago·Neutral
Avalyn Publishes Phase 1 Data Highlighting AP02's Lung-Targeted Delivery and Encouraging Safety Profile Results validate Avalyn's approach of delivering established antifibrotic medicines directly to the lungs to maximize local exposure while limiting systemic exposure and improving tolerability
View source ↗ - Newsglobenewswire.com·67d ago·Negative
Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN) (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced the appointment of Robert (Bob) J. Meyer, MD, a distinguished pulmonary physician and former senior U.S. Food and Drug Administration (“FDA”) leader, to its Board of Di…
View source ↗ - Newsglobenewswire.com·75d ago·Neutral
… reduce logistical burden may support engagement in future pulmonary fibrosis clinical studies BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced new data demonstrating predicted aerosol distribution of AP01 and survey data highlighting patient perspectives on participation in clinical studies for idiopathic …
View source ↗ - Newsglobenewswire.com·90d ago·Neutral
Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026 Presentations describe integration of patient perspective into clinical trial design and data modeling AP01 distribution in the lungs Presentations describe integration of patient perspective into clinical trial design and data modeling AP01 distribution in the lungs
View source ↗ - Newsglobenewswire.com·102d ago·Neutral
Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027 Two abstracts accepted for presentation at the European Respiratory Society (ERS) Congress, including data modeling AP01 lung tissue distribution Ended the second quarter of 2026 with $413.5 million in cash, cash equivalents and marketable securities; cash runway projected into 2029 BOSTO
View source ↗
Earnings
Thu, Feb 11(in 3 months)
Consensus estimate $-0.70 per share
Typical surprise -26.2% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 12$-0.67 vs $-0.67beat
- Wed, Aug 12$-0.98 vs $-0.78miss
- Wed, Jun 3$-21.83 vs $-5.98miss
Estimates and results for AVLN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AVLN officers and directors.
- Bought
- —
- Sold
- $6.7m
0 trades
4 trades
- Fmr Llcsold
- Fmr Llcsold
- Fmr Llcsold
- Fmr Llcsold
2 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AVLN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
